Analysts expect that OptimizeRx Co. (NASDAQ:OPRX) will announce $5.16 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for OptimizeRx’s earnings. The highest sales estimate is $5.21 million and the lowest is $5.14 million. OptimizeRx posted sales of $4.11 million in the same quarter last year, which suggests a positive year over year growth rate of 25.5%. The company is expected to issue its next earnings results on Wednesday, May 1st.
According to Zacks, analysts expect that OptimizeRx will report full-year sales of $28.79 million for the current fiscal year, with estimates ranging from $28.69 million to $28.91 million. For the next fiscal year, analysts expect that the company will report sales of $37.12 million, with estimates ranging from $37.08 million to $37.16 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for OptimizeRx.
OPRX has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of OptimizeRx from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, January 4th. William Blair initiated coverage on shares of OptimizeRx in a research report on Thursday, January 3rd. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $18.25.
NASDAQ OPRX traded down $0.70 during trading hours on Monday, reaching $12.60. The company had a trading volume of 29,441 shares, compared to its average volume of 59,679. OptimizeRx has a 1-year low of $2.30 and a 1-year high of $18.39. The stock has a market capitalization of $160.87 million, a P/E ratio of 252.00, a PEG ratio of 1.44 and a beta of 1.06.
In other OptimizeRx news, major shareholder Awm Investment Company, Inc. sold 21,397 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $15.05, for a total value of $322,024.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Several institutional investors and hedge funds have recently modified their holdings of the company. Park West Asset Management LLC lifted its position in shares of OptimizeRx by 63.3% during the fourth quarter. Park West Asset Management LLC now owns 967,448 shares of the company’s stock worth $10,613,000 after purchasing an additional 375,000 shares in the last quarter. Vanguard Group Inc acquired a new stake in shares of OptimizeRx during the third quarter worth about $5,204,000. 1492 Capital Management LLC acquired a new stake in shares of OptimizeRx during the fourth quarter worth about $1,454,000. Avenir Corp lifted its position in shares of OptimizeRx by 74.2% during the fourth quarter. Avenir Corp now owns 117,400 shares of the company’s stock worth $1,288,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Timpani Capital Management LLC lifted its position in shares of OptimizeRx by 51.5% during the fourth quarter. Timpani Capital Management LLC now owns 108,643 shares of the company’s stock worth $1,192,000 after purchasing an additional 36,949 shares in the last quarter. 45.94% of the stock is currently owned by institutional investors and hedge funds.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.
Recommended Story: What are the benefits of buying treasury bonds?
Get a free copy of the Zacks research report on OptimizeRx (OPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.